Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN G SODIUM versus VERSAPEN K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN G SODIUM versus VERSAPEN K.
PENICILLIN G SODIUM vs VERSAPEN-K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
VERSAPEN-K (hetacillin potassium) is a prodrug that is hydrolyzed to ampicillin, which inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
2-4 million units intravenously every 4 hours for moderate to severe infections; up to 24 million units/day for severe infections (e.g., meningitis, endocarditis).
250-500 mg intramuscularly or intravenously every 6 hours for moderate infections; 1-2 g every 6 hours for severe infections.
None Documented
None Documented
30-60 minutes in normal renal function; prolonged to 7-10 hours in anuria.
0.8-1.5 hours in adults with normal renal function (prolonged to 6-20 hours in severe renal impairment; dosing adjustment required when CrCl <30 mL/min).
Primarily renal (60-90% unchanged) via glomerular filtration and tubular secretion; minor biliary/fecal (<10%).
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; biliary: 15-20% as active drug; fecal: <5%.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic